Organogenesis Holdings Inc. Segments Disclosure
16. Segment Information
The Company offers a comprehensive portfolio of regenerative medicine products. The Company organizes its products into two product categories, AWC and SSM, which serve two adjacent markets. Many of the Company’s products are clinically interchangeable and certain products are categorized as both AWC and SSM products. The Company’s products all contain regenerative medicine technologies and have the same customers and target market, require similar raw materials and commercial infrastructure, and exist within the same regulatory environment.
The Company’s CODM is the . The CODM reviews consolidated gross profit and operating results to assess the overall performance of the Company, and make decisions to allocate resources among the consolidated entity. The CODM uses both gross profit and net income for the consolidated entity in the annual budget and forecasting process, and considers budget-to-actual variances in gross profit and operating expenses on a quarterly basis when making decisions about the allocation of operating and capital resources to each predominant business activity (research and development, capital expenditure, and employee headcount and compensation).
Prior period segment expense amounts have been recast to reflect the method for allocating expenses to segments in the current period.
|
|
Year Ended December 31, |
|
|||||||||
|
|
2025 |
|
|
2024 |
|
|
2023 |
|
|||
Net product revenue |
|
$ |
563,030 |
|
|
$ |
482,043 |
|
|
$ |
433,140 |
|
Grant income |
|
|
1,139 |
|
|
|
— |
|
|
|
— |
|
Less: |
|
|
|
|
|
|
|
|
|
|||
Cost of goods sold |
|
|
137,522 |
|
|
|
115,741 |
|
|
|
106,481 |
|
Clinical expense |
|
|
17,697 |
|
|
|
23,614 |
|
|
|
19,377 |
|
Sales and marketing |
|
|
214,575 |
|
|
|
203,298 |
|
|
|
180,541 |
|
General and administrative |
|
|
108,338 |
|
|
|
87,812 |
|
|
|
84,295 |
|
Other segment items (a) |
|
|
49,005 |
|
|
|
50,717 |
|
|
|
37,501 |
|
Segment net income |
|
|
37,032 |
|
|
|
861 |
|
|
|
4,945 |
|
|
|
|
|
|
|
|
|
|
|
|||
Reconciliation of segment net income: |
|
|
|
|
|
|
|
|
|
|||
Reconciling items |
|
|
— |
|
|
|
— |
|
|
|
— |
|
Consolidated net income |
|
$ |
37,032 |
|
|
$ |
861 |
|
|
$ |
4,945 |
|
(a) Other segment items include: research and development related salary, payroll taxes and benefits, research and development related rent and other facilities expense, research and development related depreciation and amortization, write-down to fair value for asset held for sale, impairment of property and construction, write-down of capitalized internal-use software costs, other income (expense), net, and income tax expense (benefit).
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Feb 26, 2026 | Showing above |
| 2024 | Feb 27, 2025 | |
About Segments Disclosures
Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.
Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.